Recognition & Referral: Best Practices for Managing Patients -

Name: Recognition & Referral: Best Practices for Managing Patients with GA - Symposium
Uploaded: 2021-12-22T05:00:00+00:00
Duration: 1 h 49 min 25 s
Description: Geographic atrophy (GA) is a progressive disease for which there is currently no FDA-approved treatment. There are, however, a number of drugs in the pipel

Media formats available:

Details

Presenters

Overview
Geographic atrophy (GA) is a progressive disease for which there is currently no FDA-approved treatment. There are, however, a number of drugs in the pipeline that are designed to address GA progression.
This previously recorded satellite symposium featuring well-known experts is designed to educate eye care providers on the importance of prompt GA diagnosis and provide the latest in-depth data on investigative therapies.
This activity is supported by an unrestricted educational grant from Apellis Pharmaceuticals.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Articulate the burden of illness linked to geographic atrophy (GA)
- Understand the pathogenesis of GA
- Describe disease detection and factors influencing progression
- Review the therapeutic interventions that have been explored as well as those in the pipeline
- Discuss the prevalence of age-related macular degeneration
Accreditation
Accreditation & Designation Statements
Provided by Evolve Medical Education

Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, earns credit toward the Lifelong Learning requirement[s] for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting credit.
Participation Method
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Faculty and Disclosures
Roger A. Goldberg, MD, MBA
Vitreoretinal Specialist
Bay Area Retina Associates
Walnut Creek, CA
Volunteer Faculty
California Pacific Medical Center
Ophthalmology Residency
San Francisco, CA

Caroline R. Baumal, MD
Professor of Ophthalmology
New England Eye Center
Tufts University School of Medicine
Boston, MA

SriniVas Sadda, MD
President and Chief Scientific Officer
Doheny Eye Institute
Professor of Ophthalmology
University of California – Los Angeles
Geffen School of Medicine
Los Angeles, CA

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Roger A. Goldberg, MD, MBA, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Carl Zeiss Meditec, Genentech, Novartis, and Regeneron Pharmaceuticals. Grant/Research Support: Aerie Pharmaceuticals, Allergan, Apellis Pharmaceuticals, Carl Zeiss Meditec, Chengdu Kanghong Biotechnology, Genentech, Graybug Vision, Neurotech, Novartis, Ribomics, and Santen. Speaker’s Bureau: Allergan and Genentech.
Caroline R. Baumal, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Genentech, Novartis, and Ora. Speaker's Bureau: Apellis and Regeneron.
SriniVas Sadda, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Amgen, Apellis Pharmaceuticals, Astellas, Bayer, CenterVue, 4DMT, Heidelerg, iveric Bio, Merck, NightStax. Novartis, Optos, Oxurion, Regeneron, and Roche/Genentech. Grant/Research Support: Carl Zeiss Meditec. Speakers Bureau: Carl Zeiss Meditec and Nidek. Research instruments: Carl Zeiss Meditec, CenterVue, Heidelberg, Nidek, Optos, and Topcon.
The Evolve staff, planners, and reviewers have no financial relationships with commercial interests.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Apellis Pharmaceuticals.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 12/22/2021
Expiration Date: 12/31/2022

Caroline R. Baumal, MD

Guest

Roger A. Goldberg, MD, MBA

Guest

SriniVas Sadda, MD

Guest

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

VBS Fellows’ Foray 2026: Through the Looking Glass—Real-World Vitreoretinal Surgical Cases
VBS Fellows’ Foray 2026: Through the Looking Glass—Real-World Vitreoretinal Surgical Cases
CME/CE
VBS Fellows’ Foray 2026: Through the Looking Glass—Real-World Vitreoretinal Surgical Cases
Yewlin E. Chee, MD; Camila Ventura MD, PhD
1.50 credits
- Yewlin E. Chee, MD
- Camila Ventura MD, PhD
- Edward Wood, MD
- Tony Capone Jr, MD
- Katherine E. Talcott, MD
- Nassim Abreu, MD
1.50 credits
Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
CME/CE Broadcast Replay
Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
Deepak Sambhara, MD
1.00 credit
- Deepak Sambhara, MD
1.00 credit
Patient at High Risk of Loss to Follow-Up, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
Patient at High Risk of Loss to Follow-Up, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
CME/CE
Patient at High Risk of Loss to Follow-Up, Part of the Focused Sight Initiative: Quality Improvement Interventions in Retinal Disease
Deepak Sambhara, MD
0.25 credits
- Deepak Sambhara, MD
0.25 credits
Phaco Reloaded: Level Up Your Cataract Game
Phaco Reloaded: Level Up Your Cataract Game
CME/CE
Phaco Reloaded: Level Up Your Cataract Game
Eric D. Donnenfeld, MD; Marjan Farid, MD
1.00 credit
- Eric D. Donnenfeld, MD
- Marjan Farid, MD
- Jason J. Jones, MD
- Eva I. Liang, MD, FACS
- Carlton Yuen, MD
1.00 credit

Recognition & Referral: Best Practices for Managing Patients with GA - Symposium

Recommended

Title